AlloVir, Inc. (NASDAQ:ALVR) CEO Diana Brainard Sells 34,435 Shares

AlloVir, Inc. (NASDAQ:ALVR – Get Rating) CEO Diana Brainard sold 34,435 shares of AlloVir stock in a transaction that occurred on Thursday, January 19th. The shares were sold at an average price of $5.08, for a total transaction of $174,929.80. Following the sale, the chief executive officer now owns 601,607 shares of the company’s stock, valued at $3,056,163.56. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Diana Brainard also recently made the following trade(s):

• On Friday, November 18th, Diana Brainard sold 4,515 shares of AlloVir stock. The shares were sold at an average price of $7.27, for a total transaction of $32,824.05.

AlloVir Price Performance

NASDAQ ALVR traded down $0.12 on Monday, hitting $5.13. The company had a trading volume of 151,167 shares, compared to its average volume of 217,905. The company has a market capitalization of $477.93 million, a PE ratio of -1.83 and a beta of 0.87. The company’s fifty day moving average price is $6.30 and its 200-day moving average price is $6.94. AlloVir, Inc. has a 12-month low of $3.17 and a 12-month high of $10.29.

AlloVir (NASDAQ:ALVR – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.02. On average, sell-side analysts anticipate that AlloVir, Inc. will post -2.28 EPS for the current year.

Institutional Investors Weigh In On AlloVir

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALVR. Amalgamated Bank purchased a new stake in shares of AlloVir during the first quarter worth $33,000. Corton Capital Inc. purchased a new stake in shares of AlloVir during the second quarter worth $41,000. SG Americas Securities LLC purchased a new stake in shares of AlloVir during the second quarter worth $49,000. Denali Advisors LLC purchased a new stake in shares of AlloVir during the third quarter worth $51,000. Finally, GMT Capital Corp grew its holdings in shares of AlloVir by 66.2% during the second quarter. GMT Capital Corp now owns 1,891,170 shares of the company’s stock worth $7,376,000 after buying an additional 753,100 shares in the last quarter.

Wall Street Analyst Weigh In

Separately, SVB Leerink cut their target price on shares of AlloVir from $25.00 to $19.00 and set an “outperform” rating for the company in a report on Monday.

About AlloVir

(Get Rating)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.